Vir Biotechnology lands a license agreement with Japan’s Astellas Pharma for its lead drug candidate.

This biotech powerhouse could maintain its strength for the long term.

This player's pipeline should keep growth going over the long run.

Biotech hot picks spotlight Xenon, United Therapeutics and Axsome as Phase III data and FDA decisions approach.

As of Monday, February 23, Fortress Biotech, Inc.’s FBIO share price has surged by 18.42%, which has investors questioning if ...

AI-assisted drug discovery isn’t just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI ...

Investing.com -- Edesa Biotech Inc (NASDAQ:EDSA) shares surged 77% Tuesday after the company reported positive additional data from a Phase 3 study of paridiprubart, showing statistically significant ...

Cory has been a professional trader for two decades. In addition to trading and investing he's widely published and coaches individual clients on the finer points of gaining an edge in the market.

Grail (GRAL) stock is plummeting after the company's three-year cancer screening trial failed to meet its main goal ...

Journey Medical dermatology revenue plus Emrosi near-term sales and a rare pediatric disease PRV from Zycubo approval. See ...

Laffont's new addition may represent an exciting recovery story.